시장보고서

상품코드

1684286

불면증 치료 시장 : 치료제 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2025-2032년)

Insomnia Therapeutics Market, By Therapeutics Type, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

불면증 치료 시장 규모는 2024년 29억 232만 달러로 평가되었고, 2025-2032년 연평균 복합 성장률(CAGR)은 4.90%를 보일 전망입니다.

불면증 치료 시장 - 시장 역학

정신질환 증가로 불면증 치료 수요 증가 견인

불안, 우울증, 스트레스 관련 장애와 같은 질환이 수면장애의 원인이 될 수 있기 때문에 정신 건강 질환 증가는 불면증 치료 수요를 크게 견인하고 있습니다. 세계보건기구(WHO)에 따르면, 우울증은 전 세계적으로 2억 8,000만 명 이상이 앓고 있으며, 수면장애는 흔한 증상입니다. 미국 국립정신건강연구소(NIMH)는 불안장애가 있는 사람은 만성 불면증에 걸릴 위험이 높다고 강조합니다. 이에 따라 불면증에 대한 인지행동치료(CBT-I)가 1차 선택 치료로 채택되고 있으며, 기존 진정제에 비해 안전성 프로파일이 개선된 이중 올레신 수용체 길항제와 같은 약리학적 해결책도 발전하고 있습니다. 또한, FDA 승인을 받은 Somryst와 같은 디지털 치료제는 정신 건강 관리 계획에 통합되어 쉽게 이용할 수 있는 비약물적 치료 옵션을 제공합니다. 정신건강과 수면장애의 연관성이 인식됨에 따라 의료 서비스 제공업체와 제약회사들은 보다 효과적이고 개인화된 불면증 치료를 개발하기 위해 노력하고 있습니다.

불면증 치료 시장 - 주요 인사이트

당사의 리서치 애널리스트들이 공유한 분석에 따르면, 세계 시장은 예측 기간(2025-2032년) 동안 연평균 약 4.90%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

치료제 유형별 세분화에 따르면, 2024년에는 비벤조디아제핀 계열이 가장 큰 시장 점유율을 차지했습니다.

약효군별로는 2024년 비벤조디아제핀계 최면제가 주요 약효군이 되었습니다.

투여 경로별로는 경구제가 2024년 주요 투여 경로가 되었습니다.

지역별로는 북미가 2024년 매출 1위를 기록했습니다.

불면증 치료 시장 - 세분화 분석 :

세계 불면증 치료 시장은 치료제 유형, 약물 유형, 약물 클래스, 투여 경로, 유통 채널, 지역에 따라 세분화됩니다.

시장은 치료제 유형에 따라 벤조디아제핀계, 비벤조디아제핀계, 항우울제, 올렉신 길항제, 멜라토닌 길항제, 기타 5가지 카테고리로 분류됩니다. 비벤조디아제핀계 항우울제는 효과와 낮은 의존성 위험으로 시장을 선도하고 있습니다. 그 뒤를 이어 올레신 길항제가 보다 안전한 대안으로 각광받고 있습니다. 항우울제는 불면증과 함께 불면증에 널리 처방되고 있지만, 벤조디아제핀 계열은 의존성 우려에도 불구하고 여전히 사용되고 있습니다. 멜라토닌 길항제 및 기타 치료제는 특정 환자들의 요구에 대응하고 있습니다.

시장은 약물 유형별로 벤조디아제핀계 최면제, 비벤조디아제핀계 최면제, 멜라토닌 수용체 작용제, 올레신 수용체 길항제, 항우울제 등 6가지 카테고리로 분류됩니다. 비벤조디아제핀계 최면제는 효과와 의존성 위험 감소로 인해 우위를 점하고 있습니다. 올레신 수용체 길항제는 보다 안전한 대안으로 빠르게 시장 점유율을 늘려가고 있습니다. 항우울제는 정신질환과 관련된 불면증에 널리 사용되고 있으며, 벤조디아제핀계 최면제와 멜라토닌 수용체 작용제는 틈새 환자층에 사용되고 있습니다.

불면증 치료 시장 - 지리적 통찰력

불면증의 높은 유병률, 정신질환 증가, 강력한 의료 인프라로 인해 북미는 불면증 치료 시장을 독점하고 있습니다. 특히 미국에서는 불면증에 대한 인지행동치료(CBT-I)와 처방약이 널리 사용되고 있으며, FDA는 Darydrexant와 같은 새로운 세대의 수면 보조제를 승인했습니다. 유럽에서도 수면장애에 대한 인식이 높아지고 정부 지원 정신 건강 이니셔티브에 힘입어 첨단 치료제에 대한 수요가 증가하고 있습니다. 독일, 영국, 프랑스 등에서는 AI를 활용한 수면 모니터링 솔루션을 통합한 디지털 치료제가 급증하고 있습니다. 아시아태평양에서는 라이프스타일의 변화, 업무 관련 스트레스, 도시화가 불면증, 특히 중국, 일본, 인도에서 불면증 발병률 증가에 기여하고 있습니다. 이들 국가에서는 허브 및 대체 수면 치료제의 사용이 증가하고 있는 것도 독특한 시장 동향을 보이고 있습니다. 반면, 라틴아메리카와 중동 및 아프리카는 신흥 시장으로, 의료 접근성 향상과 인식 개선 캠페인이 의약품 및 비의약품 불면증 치료의 점진적인 채택을 촉진하고 있습니다.

불면증 치료 시장 - 경쟁 구도:

불면증 치료 시장은 경쟁이 치열하며, 대형 제약사, 디지털 헬스 기업, 신생 바이오테크 기업들은 혁신적인 치료 솔루션에 집중하고 있습니다. 프로파일이 개선된 수보렉산트, 달리드렉산트 등 이중 올레신 수용체 길항제 등 차세대 불면증 치료를 개발하고 있습니다. 한편, 재즈 파마슈티컬스(Jazz Pharmaceuticals)나 화이자와 같은 기업들은 수면장애 치료제 포트폴리오를 지속적으로 확장하고 있습니다. 디지털 테라퓨틱스 분야도 성장하고 있으며, 피어테라퓨틱스의 Somryst와 같은 FDA 승인 솔루션은 불면증에 대한 인지행동치료(CBT-I)를 통한 비약물적 대체요법을 제공합니다. 스타트업과 하이테크 기업들은 AI를 활용한 수면 모니터링 기기 및 웨어러블 기술을 개발하여 치료 접근법을 개인화하기 위해 노력하고 있습니다. 시장의 발전에도 불구하고, 약물 의존성 우려, 규제 장벽, 한약과 같은 대체 치료법과의 경쟁 등의 문제가 시장 역학에 영향을 미치고 있습니다. 전략적 제휴, 제품 혁신, 유통망 확대는 불면증 치료 시장에서 입지를 강화하고자 하는 기업들에게 여전히 중요한 전략입니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 불면증 치료 업계

경쟁 대시보드
- Competitive Benchmarking
- Competitive Positioning
기업 개요
- Astellas Pharma Inc.
- Dr. Reddy's Laboratories Ltd.
- Eisai Co., Ltd.
- Lupin Limited
- Merck &Co., Inc.
- Mylan NV
- Paratek Pharmaceuticals, Inc.
- Pernix Therapeutics Holdings, Inc.
- Pfizer Inc.
- Sanofi SA
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Vanda Pharmaceuticals Inc.
- Others

제13장 애널리스트의 다각적 견해

LSH 25.04.15

REPORT HIGHLIGHT

Insomnia Therapeutics Market size was valued at US$ 2,902.32 Million in 2024, expanding at a CAGR of 4.90% from 2025 to 2032.

The insomnia therapeutics market focuses on treatments designed to manage and alleviate sleep disorders, particularly chronic and acute insomnia. Rising stress levels, increasing cases of mental health disorders, and lifestyle changes have significantly contributed to the growing prevalence of insomnia, with the CDC reporting that one in three adults in the U.S. does not get enough sleep. Pharmaceutical advancements, including orexin receptor antagonists like lemborexant and daridorexant, are enhancing treatment efficacy while reducing dependency risks associated with traditional benzodiazepines. Additionally, the expansion of cognitive behavioral therapy for insomnia (CBT-I) as a preferred non-pharmacological intervention is gaining traction, with digital therapeutics platforms like Somryst receiving FDA approval. However, side effects related to sedative-hypnotic drugs and the risk of dependency pose challenges to market growth. Opportunities lie in integrating AI-powered sleep monitoring devices and wearable technology, which provide personalized therapy insights. As awareness of sleep health increases, the demand for innovative and safer insomnia treatments continues to grow.

Insomnia Therapeutics Market- Market Dynamics

Rising Mental Health Disorders Driving Demand for Insomnia Therapeutics

Rising mental health disorders are significantly driving demand for insomnia therapeutics, as conditions like anxiety, depression, and stress-related disorders contribute to sleep disturbances. According to the World Health Organization (WHO), depression affects over 280 million people worldwide, with sleep issues being a common symptom. The National Institute of Mental Health (NIMH) highlights that individuals with anxiety disorders are at a higher risk of developing chronic insomnia. This has led to increased adoption of cognitive behavioral therapy for insomnia (CBT-I) as a first-line treatment, alongside advancements in pharmacological solutions such as dual orexin receptor antagonists, which offer improved safety profiles compared to traditional sedatives. Additionally, digital therapeutics like FDA-approved Somryst are being integrated into mental health care plans, providing accessible, non-drug treatment options. The growing recognition of the link between mental health and sleep disorders is pushing healthcare providers and pharmaceutical companies to develop more effective and personalized insomnia therapies.

Insomnia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2025-2032)

Based on Therapeutics Type segmentation, Nonbenzodiazepines was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, non-benzodiazepine hypnotics was the leading Drug Class in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Insomnia Therapeutics Market- Segmentation Analysis:

The Global Insomnia Therapeutics Market is segmented on the basis of Therapeutics Type, Drug Class, Route of Administration, Distribution Channel, and Region.

The market is divided into five categories based on Therapeutics Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others. Nonbenzodiazepines lead the market due to their effectiveness and lower dependency risk. Orexin antagonists follow, gaining traction as safer alternatives. Antidepressants are widely prescribed for comorbid insomnia, while benzodiazepines remain in use despite dependency concerns. Melatonin antagonists and other therapies cater to specific patient needs.

The market is divided into six categories based on Drug Class: Benzodiazepines, Non-Benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, and Antidepressants. Non-benzodiazepine hypnotics dominate due to their efficacy and reduced dependency risks. Orexin receptor antagonists are rapidly gaining market share as safer alternatives. Antidepressants are widely used for insomnia linked to mental health conditions, while benzodiazepines and melatonin receptor agonists serve niche patient segments.

Insomnia Therapeutics Market- Geographical Insights

North America dominates the insomnia therapeutics market due to high insomnia prevalence, rising mental health disorders, and strong healthcare infrastructure. The U.S., in particular, sees widespread adoption of cognitive behavioral therapy for insomnia (CBT-I) and prescription medications, with the FDA approving new-generation sleep aids like daridorexant. Europe follows closely, with increasing awareness of sleep disorders and government-backed mental health initiatives driving demand for advanced therapeutics. Countries such as Germany, the UK, and France are witnessing a surge in digital therapeutics, integrating AI-powered sleep monitoring solutions. In the Asia-Pacific region, changing lifestyles, work-related stress, and urbanization contribute to a growing insomnia burden, particularly in China, Japan, and India. The rising use of herbal and alternative sleep remedies in these countries also presents a unique market trend. Meanwhile, Latin America and the Middle East & Africa are emerging markets, where increasing healthcare access and awareness campaigns are driving gradual adoption of pharmaceutical and non-pharmaceutical insomnia treatments.

Insomnia Therapeutics Market- Competitive Landscape:

The insomnia therapeutics market is highly competitive, with pharmaceutical giants, digital health companies, and emerging biotech firms focusing on innovative treatment solutions. Leading players such as Merck & Co., Eisai Co., and Idorsia Pharmaceuticals are advancing next-generation insomnia drugs, including dual orexin receptor antagonists like suvorexant and daridorexant, which offer improved safety profiles over traditional sedatives. Meanwhile, companies like Jazz Pharmaceuticals and Pfizer continue to expand their sleep disorder drug portfolios. The digital therapeutics segment is also gaining traction, with FDA-approved solutions such as Pear Therapeutics' Somryst offering non-drug alternatives through cognitive behavioral therapy for insomnia (CBT-I). Startups and tech firms are developing AI-driven sleep monitoring devices and wearable technology to personalize treatment approaches. Despite market advancements, challenges such as drug dependency concerns, regulatory hurdles, and competition from alternative treatments like herbal remedies impact market dynamics. Strategic collaborations, product innovation, and expanding distribution networks remain key strategies for companies aiming to strengthen their market presence in insomnia therapeutics.

Recent Developments:

In July 2020, Eisai launched DAYVIGO(R) (lemborexant) in Japan, for treating insomnia. This dual orexin receptor antagonist facilitates sleep onset and maintenance. Approval was based on Phase III trials showing improved sleep compared to placebo and zolpidem, with somnolence, headache, and dizziness as main side effects.

In December 2024, Shionogi and Nxera Pharma launched QUVIVIQ(TM) (daridorexant) in Japan as a new treatment for adults with insomnia. This oral medication selectively blocks orexin receptors, promoting sleep by inhibiting excessive wakefulness. Shionogi will handle distribution and sales.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSOMNIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Astellas Pharma Inc.
Dr. Reddy's Laboratories Ltd.
Eisai Co., Ltd.
Lupin Limited
Merck & Co., Inc.
Mylan N.V.
Paratek Pharmaceuticals, Inc.
Pernix Therapeutics Holdings, Inc.
Pfizer Inc.
Sanofi S.A.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Vanda Pharmaceuticals Inc.
Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY THERAPEUTICS TYPE- MARKET ANALYSIS, 2019 - 2032

Benzodiazepines
Nonbenzodiazepines
Antidepressants
Orexin Antagonists
Melatonin Antagonists
Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Benzodiazepines
Non-Benzodiazepine Hypnotics
Melatonin Receptor Agonists
Orexin Receptor Antagonists
Antidepressants

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Sublingual
Intravenous
Transdermal
Nasal

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Clinics
Wellness Centers

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Insomnia Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Insomnia Therapeutics Market Snippet by Therapeutics Type
- 2.1.2. Insomnia Therapeutics Market Snippet by Drug Class
- 2.1.3. Insomnia Therapeutics Market Snippet by Route of Administration
- 2.1.4. Insomnia Therapeutics Market Snippet by Distribution Channel
- 2.1.5. Insomnia Therapeutics Market Snippet by Country
- 2.1.6. Insomnia Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Insomnia Therapeutics Key Market Trends

3.1. Insomnia Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Insomnia Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Insomnia Therapeutics Market Opportunities
3.4. Insomnia Therapeutics Market Future Trends

4. Insomnia Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Insomnia Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Insomnia Therapeutics Market Landscape

6.1. Insomnia Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Insomnia Therapeutics Market - By Therapeutics Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapeutics Type, 2024 & 2032 (%)
- 7.1.2. Benzodiazepines
- 7.1.3. Nonbenzodiazepines
- 7.1.4. Antidepressants
- 7.1.5. Orexin Antagonists
- 7.1.6. Melatonin Antagonists
- 7.1.7. Others

8. Insomnia Therapeutics Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 8.1.2. Benzodiazepines
- 8.1.3. Non-Benzodiazepine Hypnotics
- 8.1.4. Melatonin Receptor Agonists
- 8.1.5. Orexin Receptor Antagonists
- 8.1.6. Antidepressants

9. Insomnia Therapeutics Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Sublingual
- 9.1.4. Intravenous
- 9.1.5. Transdermal
- 9.1.6. Nasal

10. Insomnia Therapeutics Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Retail Pharmacies
- 10.1.4. Online Pharmacies
- 10.1.5. Clinics
- 10.1.6. Wellness Centers

11. Insomnia Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Insomnia Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Insomnia Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Insomnia Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Insomnia Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Insomnia Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Insomnia Therapeutics Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Astellas Pharma Inc.
- 12.2.2. Dr. Reddy's Laboratories Ltd.
- 12.2.3. Eisai Co., Ltd.
- 12.2.4. Lupin Limited
- 12.2.5. Merck & Co., Inc.
- 12.2.6. Mylan N.V.
- 12.2.7. Paratek Pharmaceuticals, Inc.
- 12.2.8. Pernix Therapeutics Holdings, Inc.
- 12.2.9. Pfizer Inc.
- 12.2.10. Sanofi S.A.
- 12.2.11. Sumitomo Dainippon Pharma Co., Ltd.
- 12.2.12. Sun Pharmaceutical Industries Ltd.
- 12.2.13. Takeda Pharmaceutical Company Limited
- 12.2.14. Teva Pharmaceutical Industries Ltd.
- 12.2.15. Torrent Pharmaceuticals Ltd.
- 12.2.16. Vanda Pharmaceuticals Inc.
- 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us